Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
SRTS Stock Overview
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
Sensus Healthcare Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$8.02 |
52 Week High | US$11.96 |
52 Week Low | US$3.21 |
Beta | 0.50 |
1 Month Change | -10.29% |
3 Month Change | -29.96% |
1 Year Change | 82.27% |
3 Year Change | 44.77% |
5 Year Change | 99.50% |
Change since IPO | 37.09% |
Recent News & Updates
Sensus Healthcare: A Buy In Honor Of Skin Cancer Awareness Month
Sensus has developed an FDA-cleared laser device that targets non-melanoma skin cancers and keloids. While 2021 was a tough time for the company as elective procedures non-existent during the pandemic. However, a swift rebound occurred of late that has driven revenues and earnings to all-time highs. I believe this trend will continue thanks to advantageous tech platform, TAM, and operational excellence.
Analysts Just Made A Captivating Upgrade To Their Sensus Healthcare, Inc. (NASDAQ:SRTS) Forecasts
Sensus Healthcare, Inc. ( NASDAQ:SRTS ) shareholders will have a reason to smile today, with the analysts making...
Investors Will Want Sensus Healthcare's (NASDAQ:SRTS) Growth In ROCE To Persist
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
Shareholder Returns
SRTS | US Medical Equipment | US Market | |
---|---|---|---|
7D | 5.2% | 7.0% | 6.6% |
1Y | 82.3% | -23.6% | -18.4% |
Return vs Industry: SRTS exceeded the US Medical Equipment industry which returned -23.7% over the past year.
Return vs Market: SRTS exceeded the US Market which returned -18.5% over the past year.
Price Volatility
SRTS volatility | |
---|---|
SRTS Average Weekly Movement | 11.1% |
Medical Equipment Industry Average Movement | 10.4% |
Market Average Movement | 8.1% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SRTS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: SRTS's weekly volatility (11%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 37 | Joe Sardano | https://www.sensushealthcare.com |
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Sensus Healthcare Fundamentals Summary
SRTS fundamental statistics | |
---|---|
Market Cap | US$133.75m |
Earnings (TTM) | US$21.30m |
Revenue (TTM) | US$34.31m |
6.3x
P/E Ratio3.9x
P/S RatioIs SRTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SRTS income statement (TTM) | |
---|---|
Revenue | US$34.31m |
Cost of Revenue | US$11.76m |
Gross Profit | US$22.55m |
Other Expenses | US$1.26m |
Earnings | US$21.30m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 1.28 |
Gross Margin | 65.73% |
Net Profit Margin | 62.07% |
Debt/Equity Ratio | 0% |
How did SRTS perform over the long term?
See historical performance and comparisonValuation
Is SRTS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SRTS?
Other financial metrics that can be useful for relative valuation.
What is SRTS's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | US$133.75m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3x |
Enterprise Value/EBITDA | 10.5x |
PEG Ratio | -0.1x |
Price to Earnings Ratio vs Peers
How does SRTS's PE Ratio compare to its peers?
SRTS PE Ratio vs Peers |
---|
Company | PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 251x |
Price-To-Earnings vs Peers: SRTS is good value based on its Price-To-Earnings Ratio (6.3x) compared to the peer average (251x).
Price to Earnings Ratio vs Industry
How does SRTS's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?
Price-To-Earnings vs Industry: SRTS is good value based on its Price-To-Earnings Ratio (6.3x) compared to the US Medical Equipment industry average (34.8x)
Price to Earnings Ratio vs Fair Ratio
What is SRTS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 6.3x |
Fair PE Ratio | 6.2x |
Price-To-Earnings vs Fair Ratio: SRTS is expensive based on its Price-To-Earnings Ratio (6.3x) compared to the estimated Fair Price-To-Earnings Ratio (6.2x).
Share Price vs Fair Value
What is the Fair Price of SRTS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SRTS ($8.02) is trading above our estimate of fair value ($3.13)
Significantly Below Fair Value: SRTS is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: SRTS's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Discover undervalued companies
Future Growth
How is Sensus Healthcare forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score
1/6Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-45.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRTS's earnings are forecast to decline over the next 3 years (-45.6% per year).
Earnings vs Market: SRTS's earnings are forecast to decline over the next 3 years (-45.6% per year).
High Growth Earnings: SRTS's earnings are forecast to decline over the next 3 years.
Revenue vs Market: SRTS's revenue (9.1% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: SRTS's revenue (9.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SRTS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has Sensus Healthcare performed over the past 5 years?
Past Performance Score
3/6Past Performance Score 3/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
34.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SRTS has a high level of non-cash earnings.
Growing Profit Margin: SRTS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: SRTS has become profitable over the past 5 years, growing earnings by 34.4% per year.
Accelerating Growth: SRTS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SRTS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: SRTS's Return on Equity (50.2%) is considered outstanding.
Discover strong past performing companies
Financial Health
How is Sensus Healthcare's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: SRTS's short term assets ($48.5M) exceed its short term liabilities ($10.3M).
Long Term Liabilities: SRTS's short term assets ($48.5M) exceed its long term liabilities ($1.2M).
Debt to Equity History and Analysis
Debt Level: SRTS is debt free.
Reducing Debt: SRTS has no debt compared to 5 years ago when its debt to equity ratio was 11%.
Debt Coverage: SRTS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: SRTS has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Dividend
What is Sensus Healthcare current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SRTS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SRTS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SRTS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SRTS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SRTS has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.4yrs
Average management tenure
CEO
Joe Sardano (68 yo)
12yrs
Tenure
US$630,451
Compensation
Mr. Joseph C. Sardano, also known as Joe, serves as Director at BioFlorida Inc since August 2021. He Co-Founded Sensus Healthcare, Inc. in 2010 and has been its Chairman of the Board, Chief Executive Offic...
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD630.45K) is about average for companies of similar size in the US market ($USD752.25K).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: SRTS's management team is considered experienced (2.4 years average tenure).
Board Members
Experienced Board: SRTS's board of directors are considered experienced (9.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SRTS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sensus Healthcare, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Sensus Healthcare, Inc.
- Ticker: SRTS
- Exchange: NasdaqCM
- Founded: 2010
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$133.754m
- Shares outstanding: 16.68m
- Website: https://www.sensushealthcare.com
Number of Employees
Location
- Sensus Healthcare, Inc.
- 851 Broken Sound Parkway NW
- Suite 215
- Boca Raton
- Florida
- 33487
- United States
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/26 00:00 |
End of Day Share Price | 2022/06/24 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.